FDA hands down approval for Bristol Myers' lung cancer drug from Turning Point buyout
Bristol Myers Squibb’s $4.1 billion buyout of Turning Point Therapeutics has paid off, with the FDA handing down an approval of the lead cancer drug in the acquisition.
Repotrectinib, which will now be marketed as Augtyro, has been approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. It will be a new rival to Pfizer’s Xalkori and Roche’s Rozlytrek in ROS1-positive NSCLC.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.